Tags

Type your tag names separated by a space and hit enter

Isradipine and dextromethorphan in methadone-maintained humans under a naloxone discrimination procedure.
Eur J Pharmacol. 2004 May 03; 491(2-3):157-68.EJ

Abstract

In seven methadone-maintained human participants trained to distinguish between a low dose of naloxone (0.15 mg/70 kg, i.m.; i.e., Drug A) and placebo (i.e., Drug B) under an instructed novel-response drug discrimination procedure, the calcium channel blocker isradipine (0-10 mg/70 kg, p.o.; N=7) and the N-methyl-D-aspartic acid (NMDA) receptor antagonist dextromethorphan (0-60 mg/70 kg, p.o.; N=6) were tested each alone and in combination with the training dose of naloxone. Isradipine alone produced some naloxone- and novel-appropriate responding, minimal changes in self-reports and decreases in blood pressure. Dextromethorphan alone produced some novel-appropriate responding and minimal changes in self-reports and vital signs. When combined with naloxone, isradipine significantly attenuated naloxone-occasioned responding, without increasing novel-appropriate responding, and attenuated naloxone-induced increases in opioid receptor antagonist ratings and ratings measuring sedation. Dextromethorphan significantly attenuated naloxone-appropriate responding, increased novel-appropriate responding, and enhanced naloxone's effects on ratings of dysphoric effects. These results suggest that isradipine attenuates and dextromethorphan enhances some of the behavioral effects of naloxone in opioid-dependent humans.

Authors+Show Affiliations

CT and VA Connecticut Healthcare System, Yale University, New Haven, 950 Campbell Avenue, Psychiatry 116A-4, Building 36, West Haven, CT 06516, USA. alison.oliveto@yale.eduNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

15140632

Citation

Oliveto, Alison, et al. "Isradipine and Dextromethorphan in Methadone-maintained Humans Under a Naloxone Discrimination Procedure." European Journal of Pharmacology, vol. 491, no. 2-3, 2004, pp. 157-68.
Oliveto A, Poling J, Kosten TR, et al. Isradipine and dextromethorphan in methadone-maintained humans under a naloxone discrimination procedure. Eur J Pharmacol. 2004;491(2-3):157-68.
Oliveto, A., Poling, J., Kosten, T. R., & Gonsai, K. (2004). Isradipine and dextromethorphan in methadone-maintained humans under a naloxone discrimination procedure. European Journal of Pharmacology, 491(2-3), 157-68.
Oliveto A, et al. Isradipine and Dextromethorphan in Methadone-maintained Humans Under a Naloxone Discrimination Procedure. Eur J Pharmacol. 2004 May 3;491(2-3):157-68. PubMed PMID: 15140632.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Isradipine and dextromethorphan in methadone-maintained humans under a naloxone discrimination procedure. AU - Oliveto,Alison, AU - Poling,James, AU - Kosten,Thomas R, AU - Gonsai,Kishorchandra, PY - 2003/11/25/received PY - 2004/03/04/revised PY - 2004/03/10/accepted PY - 2004/5/14/pubmed PY - 2005/2/8/medline PY - 2004/5/14/entrez SP - 157 EP - 68 JF - European journal of pharmacology JO - Eur J Pharmacol VL - 491 IS - 2-3 N2 - In seven methadone-maintained human participants trained to distinguish between a low dose of naloxone (0.15 mg/70 kg, i.m.; i.e., Drug A) and placebo (i.e., Drug B) under an instructed novel-response drug discrimination procedure, the calcium channel blocker isradipine (0-10 mg/70 kg, p.o.; N=7) and the N-methyl-D-aspartic acid (NMDA) receptor antagonist dextromethorphan (0-60 mg/70 kg, p.o.; N=6) were tested each alone and in combination with the training dose of naloxone. Isradipine alone produced some naloxone- and novel-appropriate responding, minimal changes in self-reports and decreases in blood pressure. Dextromethorphan alone produced some novel-appropriate responding and minimal changes in self-reports and vital signs. When combined with naloxone, isradipine significantly attenuated naloxone-occasioned responding, without increasing novel-appropriate responding, and attenuated naloxone-induced increases in opioid receptor antagonist ratings and ratings measuring sedation. Dextromethorphan significantly attenuated naloxone-appropriate responding, increased novel-appropriate responding, and enhanced naloxone's effects on ratings of dysphoric effects. These results suggest that isradipine attenuates and dextromethorphan enhances some of the behavioral effects of naloxone in opioid-dependent humans. SN - 0014-2999 UR - https://www.unboundmedicine.com/medline/citation/15140632/Isradipine_and_dextromethorphan_in_methadone_maintained_humans_under_a_naloxone_discrimination_procedure_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0014299904002614 DB - PRIME DP - Unbound Medicine ER -